BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Nanophase Technologies Corp.
1319 Marquette Drive
Romeoville IL 60446, US
Phone: (630) 771-6700; Fax: (630) 771-0825
Web: www.nanophase.com
E-mail: investor-relations@nanophase.com
KEY PERSONNEL: Donald S. Perkins; Chairman
Joseph Cross; CEO and President
Jess Jankowski; CFO
Richard W. Brotzman; VP, R&D
Robert Haines; VP, Operations
Daniel S. Bilicki; VP, Sales and Marketing
Edward G. Ludwig; VP, Business Development
EMPLOYEES: 49 employees
HISTORY: Founded in 1989 as a spinoff of Argonne National Labs
STOCK-FINANCIAL HISTORY: NASDAQ--NANX
IPO--$8/share (11/97)
Revenue $6.802M (YE 05) compared to $5.208M (YE 04)
Net loss (YE 05) compared to (YE 04)
Loss per share (YE 05) compared to (YE 04)
Average shares outstanding 17.938M (YE 05) compared to 17.266M (YE
04)
Total assets $18.173M (YE 05) compared to $21.792M (YE 04)
BUSINESS STRATEGY: Provide nanoengineered solutions for multiple industrial product applications
such as commercial quantity and quality nanoparticles, coated nanoparticles
and nanoparticle dispersions in a variety of media. Sell intermediate
products enabling high-value add customer applications. The company has
major partnerships (including BASF, Rohm & Haas and BYK Chemie)
exploiting broad applications expertise and global distribution channels.
AGREEMENTS: Name Products Content of Agreement Date
Alfa Aesar nanomaterials for distribution
10/05
(research
research and
agreement
chemicals unit of development
Johnson Matthey) applications
Competitive CT to identify
option, evaluation, 10/05
Technologies nanotechnologies that licensing and
may be synergistic with commercialization
Nanophase’s
technologies
agreement
Roche
nanoparticles for a supply agreement 3/06
Diagnostics medical diagnostics
application through
2014
PRODUCTS ON MARKET: Metal oxides
Coated metal oxides
Nanoparticle dispersions
Custom synthesis
Copyright ©2006 AHC Media ® 260